- Home
- FFR vs TVRD Comparison
FFR vs TVRD Comparison
Compare FFR & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFR | TVRD |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 27.5M |
| IPO Year | 2015 | 2013 |
Fundamental Metrics
Financial Performance| Metric | FFR | TVRD |
|---|---|---|
| Price | $1.14 | $0.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $9.25 |
| AVG Volume (30 Days) | ★ 1.2M | 210.8K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.79 | ★ 79.01 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,983,556.00 | $911,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 959.30 |
| 52 Week Low | $0.97 | $0.93 |
| 52 Week High | $2.05 | $5.69 |
Technical Indicators
Market Signals| Indicator | FFR | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 30.56 |
| Support Level | $1.05 | $0.93 |
| Resistance Level | $2.05 | $2.02 |
| Average True Range (ATR) | 0.25 | 0.08 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 15.62 | 7.12 |
Price Performance
Historical ComparisonAbout FFR FF EAI Robotics Ecosystem Inc. Common Stock
FF EAI Robotics Ecosystem Inc is a U.S.-based Embodied AI (EAI) robotics company that is in the process of acquiring the FF EAI Robotics business. The company focuses on the research and development, manufacturing, commercialization, and deployment of intelligent robotic technologies, products, and industry solutions.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.